Pregabalin Zentiva

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

pregabalin

Available from:

Zentiva, k.s.

ATC code:

N03AX16

INN (International Name):

pregabalin

Therapeutic group:

Antiepileptics,

Therapeutic area:

Anxiety Disorders; Epilepsy

Therapeutic indications:

Neuropathic pain , Pregabalin Zentiva is indicated for the treatment of peripheral and central neuropathic pain in adults. , Epilepsy , Pregabalin Zentiva is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation. , Generalised anxiety disorder , Pregabalin Zentiva is indicated for the treatment of generalised anxiety disorder (GAD) in adults.

Product summary:

Revision: 15

Authorization status:

Pooblaščeni

Authorization date:

2015-07-17

Patient Information leaflet

                                25
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Zentiva, k.s.
U Kabelovny 130
102 37 Prague 10
Češka
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/15/1021/001
EU/1/15/1021/002
EU/1/15/1021/003
EU/1/15/1021/004
EU/1/15/1021/029
EU/1/15/1021/005
EU/1/15/1021/037
EU/1/15/1021/038
EU/1/15/1021/039
EU/1/15/1021/040
EU/1/15/1021/041
EU/1/15/1021/042
13.
ŠTEVILKA SERIJE
Lot
14.
NAČIN IZDAJANJA ZDRAVILA
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Pregabalin Zentiva 25 mg
17.
EDINSTVENA OZNAKA –
DVODIMENZIONALNA ČRTNA KODA
_ _
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI_ _
PC
SN
NN
26
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI
DVOJNEM TRAKU
PRETISNI OMOTI
1.
IME ZDRAVILA
Pregabalin Zentiva 25 mg trde kapsule
pregabalin
2.
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Zentiva logo
3.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
4.
ŠTEVILKA SERIJE
Lot
5.
DRUGI PODATKI
27
PODATKI NA ZUNANJI OVOJNINI
ŠKATLA
1.
IME ZDRAVILA
Pregabalin Zentiva 50 mg trde kapsule
pregabalin
2.
NAVEDBA ENE ALI VEČ UČINKOVIN
Ena trda kapsula vsebuje 50 mg pregabalina.
3.
SEZNAM POMOŽNIH SNOVI
Vsebuje laktozo monohidrat. Za nadaljnje informacije glejte navodilo
za uporabo.
4.
FARMACEVTSKA OBLIKA IN VSEBINA
14 trdih kapsul
21 trdih kapsul
56 trdih kapsul
84 trdih kapsul
98 trdih kapsul
100 trdih kapsul
5.
POSTOPEK IN POT(I) UPORABE ZDRAVILA
za peroralno uporabo
Pred uporabo preberite priloženo navodilo!
6.
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN
POGLEDA OTROK
Zdravilo shranjujte nedosegljivo otrokom!
7.
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA
8.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
Shranjujte pri temperaturi do 25 °C.
28
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Pregabalin Zentiva 25 mg trde kapsule
Pregabalin Zentiva 50 mg trde kapsule
Pregabalin Zentiva 75 mg trde kapsule
Pregabalin Zentiva 100 mg trde kapsule
Pregabalin Zentiva 150 mg trde kapsule
Pregabalin Zentiva 200 mg trde kapsule
Pregabalin Zentiva 225 mg trde kapsule
Pregabalin Zentiva 300 mg trde kapsule
2.
KAKOVOSTNA IN
KOLIČINSKA SESTAVA
Pregabalin Zentiva 25 mg trde kapsule
Ena trda kapsula vsebuje 25 mg pregabalina.
Pomožne
snovi z znanim učinkom
Ena trda kapsula vsebuje tudi 47,57 mg laktoze monohidrata.
Pregabalin Zentiva 50 mg trde kapsule
Ena trda kapsula vsebuje 50 mg pregabalina.
Pomožne snovi z znanim učinkom
Ena trda kapsula vsebuje tudi 5 mg laktoze monohidrata.
Pregabalin Zentiva 75 mg trde kapsule
Ena trda kapsula vsebuje 75 mg pregabalina.
Pomožne snovi z znanim učinkom
Ena trda kapsula vsebuje tudi 7,5 mg laktoze monohidrata.
Pregabalin Zentiva 100 mg trde kapsule
Ena trda kapsula vsebuje 100 mg pregabalina.
Pomožne snovi z znanim učinkom
Ena trda kapsula vsebuje tudi 10 mg laktoze monohidrata.
Pregabalin Zentiva 150 mg trde kapsule
Ena trda kapsula vsebuje 150 mg pregabalina.
Pomožne snovi z znanim učinkom
Ena trda kapsula vsebuje tudi 15 mg laktoze monohidrata.
Pregabalin Zentiva 200 mg trde kapsule
Ena trda kapsula vsebuje 200 mg pregabalina.
Pomožne snovi z znanim učinkom
Ena trda kapsula vsebuje tudi 20 mg laktoze monohidrata.
Pregabalin Zentiva 225 mg trde kapsule
Ena trda kapsula vsebuje 225 mg pregabalina.
Pomožne snovi z znanim učinkom
Ena trda kapsula vsebuje tudi 22,5 mg laktoze monohidrata.
3
Pregabalin Zentiva 300 mg trde kapsule
Ena trda kapsula vsebuje 300 mg pregabalina.
Pomožne snovi z znanim učinkom
Ena trda kapsula vsebuje tudi 30 mg laktoze monohidrata.
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
trda kapsula
Pregabalin Zentiva 25 mg trde kapsule
Svetlo siv pokrovček in svetlo sivo telo; dolžine približno 15,9
mm, trda želatinasta kapsula z odtisom
"25
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 19-03-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 19-03-2024
Public Assessment Report Public Assessment Report Bulgarian 27-07-2015
Patient Information leaflet Patient Information leaflet Spanish 19-03-2024
Public Assessment Report Public Assessment Report Spanish 27-07-2015
Patient Information leaflet Patient Information leaflet Czech 19-03-2024
Public Assessment Report Public Assessment Report Czech 27-07-2015
Patient Information leaflet Patient Information leaflet Danish 19-03-2024
Public Assessment Report Public Assessment Report Danish 27-07-2015
Patient Information leaflet Patient Information leaflet German 19-03-2024
Public Assessment Report Public Assessment Report German 27-07-2015
Patient Information leaflet Patient Information leaflet Estonian 19-03-2024
Public Assessment Report Public Assessment Report Estonian 27-07-2015
Patient Information leaflet Patient Information leaflet Greek 19-03-2024
Public Assessment Report Public Assessment Report Greek 27-07-2015
Patient Information leaflet Patient Information leaflet English 19-03-2024
Public Assessment Report Public Assessment Report English 27-07-2015
Patient Information leaflet Patient Information leaflet French 19-03-2024
Public Assessment Report Public Assessment Report French 27-07-2015
Patient Information leaflet Patient Information leaflet Italian 19-03-2024
Public Assessment Report Public Assessment Report Italian 27-07-2015
Patient Information leaflet Patient Information leaflet Latvian 19-03-2024
Public Assessment Report Public Assessment Report Latvian 27-07-2015
Patient Information leaflet Patient Information leaflet Lithuanian 19-03-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 19-03-2024
Public Assessment Report Public Assessment Report Lithuanian 27-07-2015
Patient Information leaflet Patient Information leaflet Hungarian 19-03-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 19-03-2024
Public Assessment Report Public Assessment Report Hungarian 27-07-2015
Patient Information leaflet Patient Information leaflet Maltese 19-03-2024
Public Assessment Report Public Assessment Report Maltese 27-07-2015
Patient Information leaflet Patient Information leaflet Dutch 19-03-2024
Public Assessment Report Public Assessment Report Dutch 27-07-2015
Patient Information leaflet Patient Information leaflet Polish 19-03-2024
Public Assessment Report Public Assessment Report Polish 27-07-2015
Patient Information leaflet Patient Information leaflet Portuguese 19-03-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 19-03-2024
Public Assessment Report Public Assessment Report Portuguese 27-07-2015
Patient Information leaflet Patient Information leaflet Romanian 19-03-2024
Public Assessment Report Public Assessment Report Romanian 27-07-2015
Patient Information leaflet Patient Information leaflet Slovak 19-03-2024
Public Assessment Report Public Assessment Report Slovak 27-07-2015
Patient Information leaflet Patient Information leaflet Finnish 19-03-2024
Public Assessment Report Public Assessment Report Finnish 27-07-2015
Patient Information leaflet Patient Information leaflet Swedish 19-03-2024
Public Assessment Report Public Assessment Report Swedish 27-07-2015
Patient Information leaflet Patient Information leaflet Norwegian 19-03-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 19-03-2024
Patient Information leaflet Patient Information leaflet Icelandic 19-03-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 19-03-2024
Patient Information leaflet Patient Information leaflet Croatian 19-03-2024
Public Assessment Report Public Assessment Report Croatian 27-07-2015

Search alerts related to this product